Investigational Drug Details
| Drug ID: | D088 |
| Drug Name: | CP-945598 |
| Synonyms: | Otenabant; Otenabant |
| Type: | Chemical drug |
| DrugBank ID: | DB11745 |
| DrugBank Description: | Otenabant has been investigated for the treatment of Obesity. |
| PubChem ID: | 10052040 |
| CasNo: | 686344-29-6 |
| Repositioning for NAFLD: | No |
| SMILES: | O=C(N)C1(NCC)CCN(C=2N=CN=C3C2N=C(C=4C=CC=CC4Cl)N3C5=CC=C(Cl)C=C5)CC1 |
| Structure: |
|
| InChiKey: | UNAZAADNBYXMIV-UHFFFAOYSA-N |
| Molecular Weight: | 510.429 |
| DrugBank Targets: | Cannabinoid receptor 1 |
| DrugBank MoA: | Pre-clinical and clinical trial data suggest that CB-1 antagonists may have favorable effects on glucose metabolism in patients with type 2 diabetes and may also be an effective therapy for the treatment of obesity. |
| DrugBank Pharmacology: | -- |
| DrugBank Indication: | -- |
| Targets: | CNR1; CB-1 antagonist |
| Therapeutic Category: | -- |
| Clinical Trial Progress: | Phase 1 completed (NCT00706537) |
| Latest Progress: | Under clinical trials |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0286 | NCT00706537 | Phase 1 | Completed | No Results Available | July 2008 | August 13, 2009 | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title |
|---|